HSCT
FDA Approves Livtencity for Resistant Post-Transplant CMV
Although a rare disease overall, CMV is one of the most common infections experienced by both HSCT and SOT ...
NOVEMBER 24, 2021
FDA Approves Prevymis to Prevent CMV Among Stem Cell Transplant Patients
The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...
NOVEMBER 9, 2017
Load more